newsfilter
← Latest News
Earnings Call Transcripts·

CARDIFF ONCOLOGY - UBS Global Biopharma Conference Webcast - CARDIFF ONCOLOGY INC

Based on the transcript provided, here is the extraction and summary of forward-looking statements:

  • Explicit Guidance:

    • Financial Runway: Current cash of approximately $34 million (as of end of Q3) is projected to fund operations through the end of Q3 2027.
    • Phase 3 Trial Initiation: Management aims to commence the Phase 3 registration trial (CARDF004) in the first quarter of 2027, potentially utilizing a "staged initiation" approach to avoid delays.
    • Regulatory Pathway: The company targets the potential for accelerated approval based on Overall Response Rate (ORR) and durability data, alongside full approval based on Progression-Free Survival (PFS), within the same Phase 3 study.
    • Data Dissemination: Management expects to present updated data from the Chronic Myelomonocytic Leukemia (CMML) study at the upcoming American Society of Hematology (ASH) meeting in December.
  • Business-Segment Outlook:

    • Primary Indication (mCRC): The company is focused on a new treatment paradigm for first-line metastatic RAS-mutated colorectal cancer, aiming to enroll patients with all RAS mutations (PAN-RAS) rather than specific subsets.
    • Secondary Indication (CMML): Promising monotherapy signals are being observed in relapsed/refractory Chronic Myelomonocytic Leukemia (approx. 50% RAS pathway-driven); an updated analysis is pending.
    • Tertiary Indication (SCLC): Early monotherapy activity signals have been observed in Small Cell Lung Cancer, supported by a recently granted orphan drug designation.
    • Product Positioning: The lead candidate, Onvancitib (PLK1 inhibitor), is positioned to be combined with FOLFIRI + Bevacizumab (30 mg dose), identified as the optimal regimen based on superior response rates and depth of response compared to FOLFOX.
  • Market and Competitive Outlook:

    • Unmet Need: Management notes a lack of innovation in the RAS-mutated mCRC space for the past 20+ years, with current standard of care relying solely on chemotherapy and generic Bevacizumab.
    • Competitive Landscape: No other competitive therapies in development are currently addressing the front-line, pan-RAS-mutated population; competitors are targeting the larger MSS population or specific small fractions (e.g., G12C inhibitors).
    • Market Impact: The company anticipates its drug could shift clinical practice by offering a 70%+ Overall Response Rate (vs. ~42% in standard of care) and enabling curative surgery in a subset of patients by shrinking tumors sufficiently.
    • Synergy: The drug's mechanism is expected to outperform current standards by synergizing with Irinotecan via dual inhibition of angiogenesis (HIF-1-alpha) and DNA repair (PLK1), unlike Oxaliplatin which lacks this synergy.
  • Macro / Industry Outlook:

    • Regulatory Environment: The company leverages Fast-Track designation (announced Friday prior to conference) and Orphan Drug designation (CMML, SCLC) to facilitate frequent interactions with the FDA and accelerate timelines.
    • Investor/Clinical Focus: The outlook emphasizes the need for a new class of drugs that addresses the poor prognosis of RAS-mutated patients who historically have inferior survival compared to wild-type counterparts.
    • Manufacturing: Interactions with the FDA regarding manufacturing and companion diagnostics are proceeding well, indicating readiness for Phase 3 execution pending funding.
  • Strategic Initiatives:

    • Phase 3 Trial Design (CARDF004): Enrollment criteria will mirror the ongoing Phase 2, prospectively selecting all RAS mutations; the study is adequately powered for PFS but includes ORR data for potential accelerated approval.
    • Dose Selection: 30 mg Onvancitib combined with FOLFIRI + Bevacizumab has been selected as the registrational dose and regimen based on Phase 2 data (Project Optimus alignment).
    • Operational Execution: A Contract Research Organization (CRO) has been selected to support the trial; management is preparing for a potential "staged initiation" to mitigate timeline risks.
    • Pipeline Expansion: Continued investigation into CMML (monotherapy) and SCLC (monotherapy) to diversify the potential indications beyond the primary colorectal focus.
  • Risks and Headwinds to Outlook:

    • Funding Dependency: Phase 3 initiation is explicitly conditioned on funding availability ("pending funding").
    • Data Maturity: The current Phase 2 study was not powered for PFS analysis; while trends are compelling, median PFS in the treatment arm has not yet been reached, requiring the larger Phase 3 study for definitive confirmation.
    • Regulatory Uncertainty: While Fast-Track and Accelerated Approval pathways are targeted, final approval depends on the magnitude of ORR and PFS data in the larger Phase 3 trial.
    • Competitor Speed: The presence of competitors targeting MSS populations or specific RAS mutations poses a risk, though Cardiff differentiates via the pan-RAS front-line approach.
    • Clinical Execution: Risks associated with patient enrollment (including those with liver mets and multi-organ involvement) and maintaining tolerability over long treatment durations.
  • Management Tone on the Future:

    • Confidence Level: High confidence ("very compelling efficacy trends," "gives us a lot of confidence") regarding the drug's ability to change practice, driven by the significant response rate differential (70% vs 42%) and durability.
    • Strategic Caution: Tone remains measured regarding the Phase 2 PFS data (acknowledging the study was not powered for it) while expressing certainty in the biological rationale and Phase 3 design.
    • Execution Focus: Management emphasizes active execution ("working earnestly," "very well prepared") and proactive regulatory engagement rather than passive waiting.
    • Hedging: All forward-looking statements are prefaced with references to SEC filings (SSE) and risk factors, acknowledging the speculative nature of clinical trial outcomes.
  • Miscellaneous:

    • Mechanism of Action: The drug inhibits HIF-1-alpha (angiogenesis) and PLK1 (DNA repair); synergy with Irinotecan (Topoisomerase 1 inhibitor) is attributed to dual pathway inhibition, whereas Oxaliplatin lacks this synergy.
    • Patient Subgroups: The drug shows benefit across various baseline characteristics, including patients with liver metastases and those aged differently, with no single baseline characteristic negatively influencing outcomes.
    • Survival Metrics: Median PFS in the control arm is approximately 11 months; treatment arm data remains immature but shows a trend toward superior durability.
Company
CARDIFF ONCOLOGY INC
Keywords
CARDIFF ONCOLOGY INC